Friday, March 15, 2024

Time

Session

Speaker(s)

2-2:45 pm

Conference registration and reception

2:45-3 pm

Chair Introduction

David McConkey, PhD

JHU

3-4 pm

BCAN-led patient panel discussion: 

How would you feel about enrolling in a clinical trial in which your therapy would be determined based on a biomarker?

Moderator

Stephanie Chisolm, PhD

BCAN

Panelists

1. Fran Curtis, Patient Speaker

Doug MacLean, Patient Speaker

4-4:15 pm

Break

4:15-6:15 pm

Session 1: Tissue-based Genomic Biomarkers

4:15-4:20 pm

Session 1 Introduction

Moderator

Kent Mouw, MD, PhD, Dana-Farber Cancer Institute, Harvard University

4:20-4:40 pm

Interrogating the Role of Epigenetic Factors as Biomarkers of Response to Immune Checkpoint Therapy

Sangeeta Goswami, MD, PhD

MD Anderson

4:40-5:00 pm

Tumor Cell Intrinsic Drivers of Densitivity to

Chemotherapy and Radiation

Kent Mouw, MD, PhD

Dana-Farber Cancer Institute, Harvard University

5:00-5:20 pm

Biomarkers in TIME and space: is humoral immunity a missing link to prediction of response to BCG?

Madhuri Koti, DVM, MVSc., PhD

Queens University

5:20-5:40 pm

Comprehensive Evaluation of Molecular Correlates for Chemotherapeutic Response

Woonyoung Choi, PhD, MS

JHU

5:40-6:15 pm

Session 1 Panel Q&A

Moderator

Kent Mouw, MD, PhD, Dana-Farber Cancer Institute, Harvard University

Panelists

1. Sangeeta Goswami, MD, PhD, MD Anderson
2. Madhuri Koti, DVM, MVSc., PhD, Queens University
3. Woonyoung Choi, PhD, MS, JHU

6:15-7 pm

Reception with Museum Tour

Tupper Stevens, MLS

American Urological Association (AUA)

7-9:30 pm

Conference dinner

Saturday, March 16, 2024

Time

Session

Speaker

8:00 - 8:30 am

Networking breakfast

8:30 – 11:00 am

Session 2: Liquid Biopsies: Urine & Plasma

8:30 - 8:35 am

Session 2 Introduction

Moderators

1. Jonathan Dudley, MD, JHU
2. Matt Galsky, MD, Mount Sinai

8:35 - 9:00 am

Detection and surveillance of bladder cancer using urine tumor DNA

Jonathan Dudley, MD

JHU

9:00 - 9:25 am

Integrating Liquid Biopsies in Clinical Trials – Where we stand and what’s on the horizon?

Roger Li, MD

Moffitt Cancer Center

9:25 - 9:50 am

Urinary tumor DNA for simultaneous minimal residual disease detection and comprehensive genomic profiling of UC

Trevor Levin, PhD

Convergent Genomics

9:50 - 10:15 am

Advances in Molecular Diagnostics for Oncology: Signatera MRD Testing in Bladder Cancer

Minetta Liu, MD

Natera

10:15 - 10:40 am

Clinical development of ctDNA-guided therapeutic approaches in urothelial cancer

Matt Galsky, MD

Mount Sinai

10:40 – 11:00 am

Session 2 Panel Q&A

Moderators

1. Jonathan Dudley, MD, JHU
2. Matt Galsky, MD, Mount Sinai

Panelists

1. Roger Li, MD, Moffitt Cancer Center
2. Trevor Levin, PhD, Convergent Genomics
3. Minetta Liu, MD, Natera

11:00 - 11:15 am

Break

11:15 am –

12:15 pm

Microbiome Panel Discussion:

Do we have robust biomarkers?

Moderator

David McConkey, PhD, JHU

Panelists

1. Laura Bukavina, MD, Case-Western
2. Cynthia L. Sears, MD, JHU
3. Armine Smith, MD, JHU

12:15 - 1:45 pm

Networking Lunch

1:45 - 3:45 pm

Session 3: AI/Path

Moderators

1. Bishoy Faltas, MD, Weill Cornell
2. Seth Lerner, MD, Baylor College of Medicine

1:45 - 2:15 pm

Predicting Clinical Outcomes in the S1314-COXEN Trial Using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression

Bishoy Faltas, MD

Weill Cornell

2:15 - 2:45 pm

Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture

Alexander Spyridon Baras, MD, PhD

JHU

2:45 - 3:15 pm

Pathology-Based Deep Learning Tools to Personalize Treatment Decisions

Erin Stewart, PhD

ArteraAI

3:15 - 3:45 pm

Session 3 Panel Q&A

Moderators

1. Bishoy Faltas, MD, Weill Cornell
2. Seth Lerner, MD, Baylor College of Medicine

Panelists

1. Alexander Spyridon Baras, MD, PhD, JHU
2. Erin Stewart, PhD, ArteraAI

3:45 pm

Conference wrap-up and adjourn